Safety monitoring of cardiac and hepatic systems in β-thalassemia patients with chelating treatment in Taiwan

被引：52

作者：

Peng, CT

Chow, KC

Chen, JH

Chiang, YP

Lin, TY

Tsai, CH

机构：

[1] China Med Coll Hosp, Dept Paediat, Taichung 404, Taiwan

[2] China Med Coll Hosp, Dept Med Res, Taichung 404, Taiwan

[3] China Med Coll Hosp, Dept Radiol, Taichung 404, Taiwan

[4] China Med Coll Hosp, Dept Pathol, Taichung 404, Taiwan

[5] China Med Coll Hosp, Inst Med Sci, Taichung 404, Taiwan

来源：

EUROPEAN JOURNAL OF HAEMATOLOGY | 2003年 / 70卷 / 06期

关键词：

deferiprone; desferrioxamine; chelation; thalassemia; cardiac; iron overload; cardiac function; magnetic resonance imaging; left ventricular ejection fraction;

D O I：

10.1034/j.1600-0609.2003.00071.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

We conducted a prospective 3-yr clinical study comparing deferiprone (L1) with desferrioxamine (DFX). The therapeutic efficacy and potential side-effects on cardiac and/or hepatic systems of thalassemia patients were assessed by left ventricular ejection fraction, T2-weighted magnetic resonance imaging, and biochemical parameters. In both groups, levels of serum ferritin decreased significantly, and the hepatic function improved notably. Besides decrement of iron, no marked pathohistological changes were observed in the liver biopsies. These results indicated that for patients who failed to respond to DFX treatment, the use of L1 to remove excess iron deposition is recommended.

引用

页码：392 / 397

页数：6

共 33 条

[1] LONG-TERM ASSESSMENT OF EFFICACY AND SAFETY OF L1, AN ORAL IRON CHELATOR, IN TRANSFUSION DEPENDENT THALASSEMIA - INDIAN TRIAL [J].